Beryllium sensitization progresses to chronic beryllium disease: A longitudinal study of disease risk

American Journal of Respiratory and Critical Care Medicine

Volumn 171, Issue 1, 2005, Pages 54-60

  Newman, Lee S ^a   Mroz, Margaret M ^b   Balkissoon, Ronald ^b   Maier, Lisa A ^b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b NONE

Author keywords

Berylliosis; Beryllium; Lymphocyte proliferation test; Medical surveillance; Transbronchial biopsy

Indexed keywords

ADULT; ARTICLE; BERYLLIOSIS; CHRONIC DISEASE; DISEASE COURSE; ETHNOLOGY; EVALUATION; FEMALE; FOLLOW UP; GRANULOMATOUS INFLAMMATION; HUMAN; LUNG BIOPSY; LUNG LAVAGE; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MONITORING; OCCUPATIONAL HAZARD; PRIORITY JOURNAL; SENSITIZATION; SEX DIFFERENCE; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; BERYLLIOSIS; BERYLLIUM; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LONGITUDINAL STUDIES; LUNG; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PULMONARY GAS EXCHANGE; RESPIRATORY HYPERSENSITIVITY; RISK FACTORS; VITAL CAPACITY;

EID: 11144229674     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200402-190OC     Document Type: Article

References (32)

1. Kreiss K, Newman LS, Mroz MM, Campbell PA. Screening blood test identifies subclinical beryllium disease. J Occup Med 1989;31:603-608.
2. Mroz MM, Kreiss K, Lezotte DC, Campbell PA, Newman LS. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J Allergy Clin Immunol 1991;88:54-60.
3. Kreiss K, Mroz MM, Zhen B, Martyny J, Newman LS. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis 1993;148:985-991.
4. Kreiss K, Wasserman S, Mroz MM, Newman LS. Beryllium disease screening in the ceramics industry: blood lymphocyte test performance and exposure-disease relations. J Occup Med 1993;35:267-274.
5. 3. Am J Ind Med 1996;30:16-25.
6. Stange AW, Furman FJ, Hilmas DE. Rocky Flats beryllium health surveillance. Environ Health Perspect 1996;104:981-986.
7. Kreiss K, Mroz MM, Zhen B, Wiedemann H, Barna B. Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup Environ Med 1997;54:605-612.
8. Stange AW, Hilmas DE, Furman FJ, Gatliffe TR. Beryllium sensitization and chronic beryllium disease at a former nuclear weapons facility. Appl Occup Environ Hyg 2001;16:405-417.
9. Newman LS, Mroz MM, Maier LA, Daniloff EM, Balkissoon R. Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant. J Occup Environ Med 2001;43:231-237.
10. Henneberger PK, Cumro D, Deubner DD, Kent MS, McCawley M, Kreiss K. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health 2001;74:167-176.
11. Deubner DC, Kelsh M, Shum M, Maier L, Kent MS, Lau E. Beryllium sensitization, chronic beryllium disease, and exposures at a beryllium mining and extraction facility. Appl Occup Environ Hyg 2001;16:579-592.
12. Newman LS. Significance of the blood beryllium lymphocyte proliferation test (BeLPT). Environ Health Perspect 1996;104:953-956.
13. Newman LS, Balkissoon R, Daniloff E, Solida M, Mroz M. Rate of progression from beryllium sensitization to chronic beryllium disease is 9-19% per year [abstract]. Am J Respir Crit Care Med 1998;157:A145.
14. Maier LA, Newman LS. Beryllium disease. In: Rom WN, editor. Environmental and occupational medicine, 3rd ed. Philadelphia, PA: Lippincott-Raven; 1998. pp. 1017-1031.
15. International Labor Organization. Guidelines for the use of ILO international classification of radiographs of pneumoconioses. Geneva, Switzerland: International Labour Office; 1980.
16. Ogilvie CM, Forster RE, Blakemore WS, Morton JW. A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide. J Clin Invest 1957;36:1-17.
17. Lundgren RA, Maier LA, Rose CS, Balkissoon RC, Newman LS. Indirect and direct gas exchange at maximum exercise in beryllium sensitization and disease. Chest 2001;120:1702-1708.
18. Newman LS, Kreiss K, King TE Jr. Pathologic and immunologic alterations in early stages of beryllium disease. Am Rev Respir Dis 1989;139:1479-1486.
19. Barna BP, Culver DA, Yen-Lieberman B, Dweik RA, Thomassen MJ. Clinical application of beryllium lymphocyte proliferation testing. Clin Diagn Lab Immunol 2003;10:990-994.
20. Dutra FR. The pneumonitis and granulomatosis peculiar to beryllium workers. Am J Pathol 1948;24:1137-1165.
21. Tepper LB, Hardy HL, Chamberlin RI. Toxicity of beryllium compounds. In: Browning E, editor. Elsevier monographs on toxic agents. Amsterdam: Elsevier; 1961. p. 93-99.
22. Pappas GP, Newman LS. Early pulmonary physiologic abnormalities in beryllium disease. Am Rev Respir Dis 1993;148:661-666.
23. Roethe RA, Fuller PB, Byrd RB, Hafermann DR. Transbronchoscopic lung biopsy in sarcoidosis: optimal number and sites for diagnosis. Chest 1980;77:400-402.
24. 2+ stores. J Pharmacol Exp Ther 2000;293:166-171.
25. Kelleher PC, Martyny JW, Mroz MM, Maier LA, Ruttenber AJ, Young DA, Newman LS. Beryllium particulate exposure and disease relations in a beryllium machining plant. J Occup Environ Med 2001;43:238-249.
26. Richeldi L, Sorrentino R, Saltini C. HLA-DPβ1 glutamate 69: a genetic marker of beryllium disease. Science 1993;262:242-244.
27. Richeldi L, Kreiss K, Mroz MM, Zhen B, Tartoni P, Saltini C. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am J Ind Med 1997;32:337-340.
28. Wang Z, Farris GM, Newman LS, Shou Y, Maier LA, Smith HN, Marrone BL. Beryllium sensitivity is linked to HLA-DP genotype. Toxicology 2001;165:27-38.
29. Maier LA, Sawyer RT, Bauer RA, Kittle LA, Lympany P, McGrath D, Dubois R, Daniloff E, Rose CS, Newman LS. High beryllium-stimulated TNF-α is associated with the -308 TNF-α promoter polymorphism and with clinical severity in chronic beryllium disease. Am J Respir Crit Care Med 2001;164:1192-1199.
30. Saltini C, Richeldi L, Losi M, Amicosante M, Voorter C, van den Berg-Loonen E, Dweik RA, Wiedemann HP, Deubner DC, Tinelli C. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J 2001;18:677-684.
31. Rossman MD, Stubbs J, Lee CW, Argyris E, Magira E, Monos D. Human leukocyte antigen class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med 2002;165:788-794.
32. Maier LA, McGrath DS, Sato H, Lympany P, Welsh K, Du Bois R, Silveira L, Fontenot AP, Sawyer RT, Wilcox E, et al. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol 2003;171:6910-6918.